Quest Diagnostics (DGX) Equity Average (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Equity Average data on file, last reported at $7.4 billion in Q1 2026.

• Quarterly Equity Average rose 7.7% year-over-year to $7.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 billion (up 7.7% YoY) and the FY2025 annual result came in at $7.0 billion, up 6.29% from the prior year.
• Equity Average improved to $7.4 billion in Q1 2026 per DGX's latest filing, from $7.2 billion in the prior quarter.
• The five-year high for Equity Average was $7.4 billion in Q1 2026, with the low at $6.0 billion in Q1 2023.
• Average Equity Average over 5 years is $6.6 billion, with a median of $6.4 billion recorded in 2022.
• Year-over-year, Equity Average decreased 6.82% in 2023 and rose 8.4% in 2025.
• Quest Diagnostics' Equity Average stood at $6.1 billion in 2022, then advanced by 4.94% to $6.4 billion in 2023, then advanced by 6.63% to $6.8 billion in 2024, then rose by 5.67% to $7.2 billion in 2025, then rose by 2.83% to $7.4 billion in 2026.
• Business Quant data shows DGX's Equity Average at $7.4 billion in Q1 2026, $7.2 billion in Q4 2025, and $7.3 billion in Q3 2025.